cerlapirdine

Small moleculeexperimental

Cerlapirdine is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011. — Wikipedia

Clinical trial activity

12 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
10
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2006 (NCT00479297)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCCOc1ccc2[nH]nc(S(=O)(=O)c3cccc4ccccc34)c2c1
Mol. weight
409.51 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cerlapirdine
  • cerlapirdine
  • cerlapirdine
  • pf-05212365
  • pf-05212365
  • pf-05212365
  • sam-531
  • sam-531
  • sam-531
  • sam-531
  • way-262531
  • way-262531
  • way-262531

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01253655Phase 1Nov 1, 2010Pfizer, Yale University
NCT00966966Phase 1Sep 1, 2009Pfizer
NCT00906191Phase 1May 1, 2009Pfizer, Wyeth
NCT00895895Phase 2May 1, 2009Pfizer
NCT00745576Phase 1Oct 1, 2008Pfizer, Wyeth
NCT00726115Phase 1Aug 1, 2008Pfizer, Wyeth
NCT00519298Phase 1Oct 1, 2007Pfizer, Wyeth
NCT00481520Phase 2Jun 1, 2007Pfizer, Wyeth
NCT00479349Phase 1May 1, 2007Pfizer, Wyeth
NCT00480818Phase 1Sep 1, 2006Pfizer, Wyeth
NCT00479297Phase 1May 1, 2006Pfizer, Wyeth
NCT00479700Phase 1May 1, 2006Pfizer, Wyeth
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit121222006
WyethFor profit9022006
Yale UniversityAcademic/Hospital1012010
3 organizations
Page 1 / 1